SCHEMBL9106523

SCHEMBL9106523

Nc1c2c(nc3ccccc13)C1CCC2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 8/20 1.00
BCHE P06276 1/20 1.00
ALDH1A1 P00352 2/20 0.48
KCNH2 Q12809 2/20 0.48
KDM4E B2RXH2 1/20 0.48
GLA P06280 1/20 0.48
CHRM2 P08172 1/20 0.48
ADRA2A P08913 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48
HPGD P15428 1/20 0.48
NQO2 P16083 1/20 0.48
MAOA P21397 1/20 0.48
DRD1 P21728 1/20 0.48
SLC6A2 P23975 1/20 0.48
CASP1 P29466 1/20 0.48
ADRA1A P35348 1/20 0.48
OPRM1 P35372 1/20 0.48
CASP7 P55210 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL10656143 0.98 ACHE (0.97) ACHEBCHEALDH1A1KCNH2KDM4E
SCHEMBL9107151 0.90 ACHE (0.82) ACHEBCHEALDH1A1KCNH2KDM4E
SCHEMBL9583069 0.80 ACHE (0.67) ACHEBCHE
SCHEMBL9107818 0.79 ACHE (0.71) ACHEBCHEKDM4ESMN1; SMN2
SCHEMBL9107842 0.79 ACHE (1.00) ACHEBCHECHRM1
SCHEMBL9107496 0.79 ACHE (0.71) ACHEBCHE
SCHEMBL9104297 0.79 ACHE (0.71) ACHEBCHE
SCHEMBL9584001 0.79 ACHE (1.00) ACHEBCHE
SCHEMBL9172816 0.78 ACHE (0.63) ACHEBCHEALDH1A1KCNH2KDM4E
SCHEMBL9171459 0.78 ACHE (0.63) ACHEBCHEALDH1A1KCNH2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0311303-B1 4-aminopyridine derivatives PFIZER (US) 1995-05-24 EP claimed
US-4897400-A ENHANCING MEMORY HOESCHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1990-01-30 US claimed
WO-1989002740-A1 4-AMINOPYRIDINE DERIVATIVES PFIZER INC. (US) 1989-04-06 WO claimed
WO-1989002739-A1 4-AMINOPYRIDINE DERIVATIVES PFIZER INC. (US) 1989-04-06 WO claimed
WO-2012170599-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS, INC. (US) 2012-12-13 WO disclosed
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS INC. (US) 2011-12-29 US disclosed
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION BRAINCELLS INC. (US) 2011-12-29 US disclosed
EP-0311303-B1 4-aminopyridine derivatives PFIZER (US) 1995-05-24 EP disclosed
US-5401749-A Memory enhancers, cholinergic agents HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1995-03-28 US disclosed
EP-0278499-B1 9-Amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds, intermediates and a process for the preparation thereof and their use as medicaments HOECHST ROUSSEL PHARMA (US) 1994-09-28 EP disclosed
US-5232927-A Useful for enhancing memory HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1993-08-03 US disclosed
US-5202440-A Certain 9-amino-2-(or 4)-oxa 1,2,3,4-tetrahydro- or 1,2,3,4,5,6,7,8-octahydro-acridines PFIZER INC. (US) 1993-04-13 US disclosed
US-5037833-A Anticholinergic agents; alzheimer's disease HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-08-06 US disclosed
US-4897400-A ENHANCING MEMORY HOESCHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1990-01-30 US disclosed
EP-0311303-A2 4-aminopyridine derivatives PFIZER INC. (US) 1989-04-12 EP disclosed
WO-1989002740-A1 4-AMINOPYRIDINE DERIVATIVES PFIZER INC. (US) 1989-04-06 WO disclosed
WO-1989002739-A1 4-AMINOPYRIDINE DERIVATIVES PFIZER INC. (US) 1989-04-06 WO disclosed
EP-0306826-A1 N-(substituted alkylidene)fused bicycloalkylidene and hetero-alkylidene quinolinamines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-03-15 EP disclosed
EP-0278499-A2 9-Amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds, intermediates and a process for the preparation thereof and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-08-17 EP disclosed
EP-0268871-A1 Quinoline derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1988-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319386-A1 NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION CHRNB2, CHAT, CHRNB4 ACHE 18/4885BCHE 42/4885ALDH1A1 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.